
May 18, 2023
TLR7: A promising drug target for lupus
Loading...
Exploring the Latest Developments in Multiple Sclerosis: A 5-Year Overview
As we celebrate World MS Day on 30th May 2023, it’s a great opportunity to reflect on the significant strides that have been made in MS research over the past 5 years.
Loading...
From AI to Impact: How GPT Applications are Accelerating Drug Discovery [Webinar]
Causaly cofounders Yiannis Kiachopoulos and Artur Saudabayev hosted a webinar, “From AI to Impact”, in April 2023, exploring the transformative power of AI and GPT applications in early drug discovery. During this captivating session, they demonstrated how Causaly combines visual evidence with high precision knowledge graphs to answer complex research questions in mechanistic biology.
Loading...
Strong growth in autoimmune drug target discovery in 2022
Two targets were chosen for their novelty – transcription factor CEBPB and transport protein MX2, both reported to be associated to Lupus in 2022.
Loading...
TLR7: A promising drug target for lupus
Toll-like receptor 7 (TLR7) has long been implicated in lupus. Now scientists are uncovering precisely how.
Loading...
Momentum builds in lupus R&D
Lupus is an autoimmune disease which affects about 1 in 1000 people, which commonly causes joint pain, skin rashes and tiredness. Treatment options are improving for patients with lupus, and the target discovery landscape is heating up.